Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $29.17.
A number of research analysts recently commented on CELC shares. Lifesci Capital assumed coverage on Celcuity in a report on Monday, August 26th. They issued an "outperform" rating and a $27.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Celcuity in a report on Friday, November 15th. Stifel Nicolaus lifted their price target on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th.
Read Our Latest Report on CELC
CELC opened at $12.00 on Friday. The company's 50 day simple moving average is $14.14 and its two-hundred day simple moving average is $15.40. The firm has a market capitalization of $445.56 million, a price-to-earnings ratio of -4.60 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a 1-year low of $11.51 and a 1-year high of $22.19.
A number of large investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in Celcuity in the third quarter valued at approximately $33,000. Prospera Private Wealth LLC acquired a new position in shares of Celcuity in the 3rd quarter valued at $35,000. Values First Advisors Inc. purchased a new stake in Celcuity in the 3rd quarter valued at $86,000. Quest Partners LLC raised its position in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after purchasing an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Celcuity during the 3rd quarter worth $119,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.